<!DOCTYPE html>
<html>

<!-- Mirrored from mullinslab.microbiol.washington.edu/publications/1918-Neutralization-profiles-of-HIV-1-viruses-from-the-VRC01-Antibody-Mediated-Prevention-AMP-trials by HTTrack Website Copier/3.x [XR&CO'2014], Mon, 21 Jul 2025 18:05:25 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    
<title>Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials | Mullins Molecular Retrovirology Lab</title>

    
    <link rel="stylesheet" href="style.css" />
    
    <link rel="alternate" type="application/atom+xml" title="Atom feed" href="feed" />
    <meta name="viewport" content="width=device-width, initial-scale=1">
    <script src='https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js?config=TeX-MML-AM_CHTML' async></script>

    <!-- Global site tag (gtag.js) - Google Analytics -->
    <script async src="https://www.googletagmanager.com/gtag/js?id=UA-136625084-1"></script>
    <script>
      window.dataLayer = window.dataLayer || [];
      function gtag(){dataLayer.push(arguments);}
      gtag('js', new Date());

      gtag('config', 'UA-136625084-1');
    </script>
</head>
<body id="entry">

<div id="container">

<header>

<h1>Mullins Molecular Retrovirology Lab</h1>

<div class="description">
<ul>
<li>Department of Microbiology</li>
<li>School of Medicine</li>
<li>University of Washington</li>
</ul>

</div>


</header>

<section id="nav">
    <nav>
        
        <ul>
            <li class=""><a href="../index.html">Home</a></li>
            <li class=""><a href="../research/index.html">Research</a></li>
            <li class="here"><a href="index.html">Publications</a><ul><li><a href="supplemental.html">Supplemental Data</a></li></ul></li>
            <li class=""><a href="../protocols/index.html">Protocols</a></li>
            <li class=""><a href="../people/index.html">People</a></li>
            <li class=""><a href="../contact/index.html">Contact</a></li>
            <li class=""><a href="../help/index.html">Help</a></li>
        </ul>
    </nav>
</section>

<section id="links">
    <nav id="quicklinks">
        <h2>Software &amp; Tools</h2>

        <ul>
            <li><a href="http://indra.mullins.microbiol.washington.edu/">Bioinformatics Tools</a></li>
            <li><a href="https://github.com/mullinslab">GitHub</a></li>
            <li><a href="../hiris/index.html">HIRIS</a></li>
            <li><a href="../HMA/index.html">HMA Subtyping Kit</a></li>
            <li><a href="../isdb/index.html">ISDB</a></li>
            <li><a href="../tcozy/index.html">TCozy</a></li>
            <li><a href="https://viroverse.washington.edu/">Viroverse</a></li>
        </ul>
    </nav>

    <nav id="lablinks">
        <h2>Lab Links</h2>

        <ul>
            <li><a href="https://hercules.mullins.microbiol.washington.edu/pub/doc/">Computing Docs</a></li>
            <li><a href="../hiris/private/index.html">HIRIS (Private)</a></li>
            <li><a href="https://tcozy.mullins.microbiol.washington.edu/ice-floe/">ICE Floe</a></li>
            <li><a href="https://hercules.mullins.microbiol.washington.edu/git/">Internal Git</a></li>
            <li><a href="../twiki/index.html">Internal wiki</a></li>
            <li><a href="https://viroverse.washington.edu/viroblast/">Local ViroBLAST</a></li>
            <li><a href="https://redash.mullins.microbiol.washington.edu/">Redash</a></li>
            <li><a href="https://mullinslab.slack.com/">Slack</a></li>
            <li><a href="../support/index.html">Ticketing system</a></li>
        </ul>
    </nav>

</section>

<div id="cfar"><a href="http://cfar.washington.edu/">
    <img src="../static/_img/2c/47ca/CFAR-logo-rev-10-22-18_4aa6fe47bc_500x157.jpg" width="500" height="157" srcset="/static/_img/2c/47ca/CFAR-logo-rev-10-22-18_4aa6fe47bc_500x157.jpg 1x, /static/_img/2c/47ca/CFAR-logo-rev-10-22-18_4aa6fe47bc_1000x314.jpg 2x" alt="University of Washington/Fred Hutch Center for AIDS Research">
</a></div>

<section id="content">
    
<!-- source file: content/publications/Mkhize_2023_NeutralizationProfilesVRC01.md -->
<article>

<div id="intro">
    <h1>Citation Information</h1>
<p>Mkhize, N.N., Yssel, A.E.J., Kaldine, H., van Dorsten, R.T., Woodward Davis, A.S., Beaume, N., Matten, D., Lambson, B., Modise, T., Kgagudi, P., York, T., Westfall, D.H., Giorgi, E.E., Korber, B., Anthony, C., Mapengo, R.E., Bekker, V., Domin, E., Eaton, A., Deng, W., DeCamp, A., Huang, Y., Gilbert, P.B., Gwashu-Nyangiwe, A., Thebus, R., Ndabambi, N., Mielke, D., Mgodi, N., Karuna, S., Edupuganti, S., Seaman, M.S., Corey, L., Cohen, M.S., Hural, J., McElrath, M.J., Mullins, J.I., Montefiori, D., Moore, P.L., Williamson, C., Morris, L., (2023)<span class="title">Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials</span><cite class="journalName">PLoS Pathog.</cite> 2023 Jun 29;19(6):e1011469(<a href="http://ncbi.nlm.nih.gov/pubmed/37384759">pubmed</a>) (<a href="https://doi.org/10.1371/journal.ppat.1011469">doi</a>)</p>
</div>


<div id="more">
    <h1>Abstract</h1>
<p>The VRC01 Antibody Mediated Prevention (AMP) efficacy trials conducted between 2016 and 2020 showed for the first time that passively administered broadly neutralizing antibodies (bnAbs) could prevent HIV-1 acquisition against bnAb-sensitive viruses. HIV-1 viruses isolated from AMP participants who acquired infection during the study in the sub-Saharan African (HVTN 703/HPTN 081) and the Americas/European (HVTN 704/HPTN 085) trials represent a panel of currently circulating strains of HIV-1 and offer a unique opportunity to investigate the sensitivity of the virus to broadly neutralizing antibodies (bnAbs) being considered for clinical development. Pseudoviruses were constructed using envelope sequences from 218 individuals. The majority of viruses identified were clade B and C; with clades A, D, F and G and recombinants AC and BF detected at lower frequencies. We tested eight bnAbs in clinical development (VRC01, VRC07-523LS, 3BNC117, CAP256.25, PGDM1400, PGT121, 10-1074 and 10E8v4) for neutralization against all AMP placebo viruses (n = 76). Compared to older clade C viruses (1998-2010), the HVTN703/HPTN081 clade C viruses showed increased resistance to VRC07-523LS and CAP256.25. At a concentration of 1ug/ml (IC80), predictive modeling identified the triple combination of V3/V2-glycan/CD4bs-targeting bnAbs (10-1074/PGDM1400/VRC07-523LS) as the best against clade C viruses and a combination of MPER/V3/CD4bs-targeting bnAbs (10E8v4/10-1074/VRC07-523LS) as the best against clade B viruses, due to low coverage of V2-glycan directed bnAbs against clade B viruses. Overall, the AMP placebo viruses represent a valuable resource for defining the sensitivity of contemporaneous circulating viral strains to bnAbs and highlight the need to update reference panels regularly. Our data also suggests that combining bnAbs in passive immunization trials would improve coverage of global viruses.</p>
</div>


<div class="clear"></div>
</article>

</section>

</div>
</body>
<!-- Mirrored from mullinslab.microbiol.washington.edu/publications/1918-Neutralization-profiles-of-HIV-1-viruses-from-the-VRC01-Antibody-Mediated-Prevention-AMP-trials by HTTrack Website Copier/3.x [XR&CO'2014], Mon, 21 Jul 2025 18:05:25 GMT -->
</html>